<DOC>
	<DOCNO>NCT00002789</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell bone marrow transplantation may able replace immune cell destroy chemotherapy use kill tumor cell . Sometimes transplanted cell make immune response body 's normal tissue . Stem cell treat laboratory filgrastim may prevent happen . Combining chemotherapy bone marrow peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . It yet know treatment effective chronic myeloid leukemia . PURPOSE : Randomized phase III trial compare effectiveness donor peripheral stem cell transplantation donor bone marrow transplantation treat patient chronic myeloid leukemia .</brief_summary>
	<brief_title>Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Chronic Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare incidence persistent cytogenetic hematologic relapse patient chronic myeloid leukemia chronic accelerate phase treat transplantation use filgrastim ( G-CSF ) -mobilized peripheral blood stem cell vs bone marrow HLA-identical , related donor . II . Compare survival nonrelapse mortality patient treat regimen . III . Compare incidence severity acute chronic graft versus host disease patient treat regimen . IV . Compare hospitalization treatment associate expense patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( 15-39 v 40-65 ) , interval diagnosis transplantation ( 2 year vs 2 year , permutation patient donor gender . Patients randomize one two treatment arm . Arm I : Patients receive preparative regimen comprise busulfan orally IV 4 time daily day -7 -4 cyclophosphamide IV day -3 -2 . Allogeneic filgrastim ( G-CSF ) -mobilized peripheral blood stem cell infuse day 0 . Arm II : Busulfan cyclophosphamide administer arm I. Allogeneic bone marrow infuse day 0 . Patients receive graft-versus-host disease prophylaxis comprise methotrexate IV day 1 , 3 , 6 , 11 cyclosporine IV 1-4 hour orally every 12 hour day -1 80 tapered . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 100 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myeloid leukemia ( CML ) chronic phase No chromosomal abnormality single Philadelphia chromosome ( Ph ) less 10 % blast bone marrow peripheral blood OR Diagnosis CML accelerate phase Must meet 1 follow criterion : More 10 % le 30 % myeloblast plus promyelocytes bone marrow peripheral blood Major perturbation WBC , platelet count , hematocrit uncontrolled chemotherapy busulfan hydroxyurea Progressive splenomegaly Extramedullary tumor Presence nonconstitutional cytogenetic abnormality addition single Ph chromosome Persistent unexplained fever bone pain Ph positive OR bcr/abl positive reversetranscriptase polymerase chain reaction Southern blot No CML blast phase PATIENT CHARACTERISTICS : Age : 15 65 Performance status : Not specify Life expectancy : At least 6 month base concurrent nonmalignant disease Hematopoietic : Not specify Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) ( unless due CML ) SGOT SGPT great 2 time ULN ( unless due CML ) Renal : Creatinine great 1.4 mg/dL Cardiovascular : Cardiac ejection fraction least 45 % Pulmonary : DLCO least 50 % predict Other : HIV negative Donor Entry Criteria : HLAidentical family member No psychological , physiological , medical condition would preclude harvest peripheral blood stem cell bone marrow HIV negative Hepatitis A , B , C antigen negative Negative pregnancy test Age 12 year PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
</DOC>